|
WUMC Cancer and Leukemia Group B
|
5U10CA077440-16
|
$320,126
|
$38,415
|
BARTLETT, NANCY
|
WASHINGTON UNIVERSITY
|
|
WESTERN ONCOLOGY RESEARCH CONSORTIUM
|
5U10CA045377-27
|
$589,569
|
$64,853
|
Conlin, Alison
|
PROVIDENCE PORTLAND MEDICAL CENTER
|
|
Virginia Mason Community Clinical Oncology Program
|
5U10CA035192-29
|
$612,504
|
$104,126
|
Nichols, Craig
|
BENAROYA RESEARCH INST AT VIRGINIA MASON
|
|
VCU Minority-Based Community Clinical Oncology Program
|
3U10CA052784-23S1
|
$125,000
|
$27,500
|
Hackney, Mary
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
VCU Minority-Based Community Clinical Oncology Program
|
5U10CA052784-23
|
$431,709
|
$94,976
|
Hackney, Mary
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
UPSTATE CAROLINA COMMUNITY CLINICAL ONCOLOGY PROGRAM
|
5U10CA035119-29
|
$1,065,000
|
$181,050
|
Bearden, James
|
SPARTANBURG REGIONAL MEDICAL CENTER
|
|
UNMC Eppley Cancer Center Support Grant
|
5P30CA036727-27
|
$1,397,496
|
$83,850
|
COWAN, KENNETH
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
|
University of Texas SPORE in Lung Cancer
|
3P50CA070907-15S1
|
$560,104
|
$28,005
|
MINNA, JOHN
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
University of Rochester Cancer Center CCOP Research Base
|
5U10CA037420-29
|
$2,114,386
|
$1,036,049
|
Morrow, Gary
|
UNIVERSITY OF ROCHESTER
|
|
University of Michigan Comprehensive Cancer Center Support Grant
|
3P30CA046592-25S1
|
$74,531
|
$745
|
WICHA, MAX
|
UNIVERSITY OF MICHIGAN
|
|
University of Michigan Comprehensive Cancer Center Support Grant
|
3P30CA046592-25S2
|
$49,999
|
$500
|
WICHA, MAX
|
UNIVERSITY OF MICHIGAN
|
|
University of Michigan Comprehensive Cancer Center Support Grant
|
5P30CA046592-25
|
$5,801,264
|
$58,013
|
WICHA, MAX
|
UNIVERSITY OF MICHIGAN
|
|
University of Maryland Greenebaum Cancer Center Support Grant
|
5P30CA134274-06
|
$1,463,426
|
$29,269
|
CULLEN, KEVIN
|
UNIVERSITY OF MARYLAND BALTIMORE
|
|
University of Colorado Southwest Oncology Group
|
5U10CA042777-26
|
$1
|
$0
|
ELIAS, ANTHONY
|
UNIVERSITY OF COLORADO DENVER
|
|
Understanding resistance in the HER2-HER3 tumor drive
|
2R01CA122216-06A1
|
$295,885
|
$73,971
|
MOASSER, MARK
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
U10 Full Member Application Affiliated with SWOG
|
5U10CA105409-10
|
$341,201
|
$61,416
|
Eng, Cathy
|
UT MD ANDERSON CANCER CTR
|
|
Tumor-targeted Polymersomes to image and Treat Ovarian Cancer
|
1R01CA175480-01A1
|
$342,934
|
$171,467
|
Cheng, Zhiliang
|
UNIVERSITY OF PENNSYLVANIA
|
|
Tumor -Targeting Chemotherapeutic Agents
|
5R01CA103314-22
|
$295,691
|
$295,691
|
OJIMA, IWAO
|
STATE UNIVERSITY NEW YORK STONY BROOK
|
|
Tulane Medical/Cancer Center Minority-Based Community Clinical Oncology Program
|
5U10CA167782-02
|
$663,700
|
$66,370
|
Robinson, William
|
TULANE UNIVERSITY OF LOUISIANA
|
|
Transport of Large Molecules and Viral Vectors in Tumors: Effects of Cytotoxic an
|
5R01CA098706-10
|
$262,036
|
$131,018
|
BOUCHER, YVES
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Transgenic Models for Prostate and Breast Cancer
|
ZIA BC 005740
|
$769,934
|
$15,399
|
Green, Jeffrey
|
CCR (NCI)
|
|
Total Synthesis and Biosynthesis of Bioactive Substances
|
5R01CA070375-17
|
$200,594
|
$100,297
|
WILLIAMS, ROBERT
|
COLORADO STATE UNIVERSITY
|
|
TOLEDO COMMUNITY CLINICAL ONCOLOGY PROGRAM
|
5U10CA035415-30
|
$676,878
|
$67,688
|
MOWAT, REX
|
TOLEDO COMMUNITY HOSPITAL ONCOLOGY PROG
|
|
Therapeutic Targeting Agents for Ovarian Cancer
|
3R01CA115483-09S1
|
$47,539
|
$23,770
|
LAM, KIT
|
UNIVERSITY OF CALIFORNIA DAVIS
|
|
Therapeutic Targeting Agents for Ovarian Cancer
|
5R01CA115483-09
|
$279,713
|
$139,857
|
LAM, KIT
|
UNIVERSITY OF CALIFORNIA DAVIS
|
|
Theranostic nanoparticles for the treatment of RAI refractory thyroid cancer
|
1R01CA178007-01
|
$351,713
|
$175,857
|
Jin, Moonsoo
|
WEILL MEDICAL COLL OF CORNELL UNIV
|
|
The University of Texas M. D. Anderson Cancer Center SPORE in Ovarian Cancer
|
3P50CA083639-14S1
|
$31,250
|
$1,875
|
BAST, ROBERT
|
UT MD ANDERSON CANCER CTR
|
|
The University of Texas M. D. Anderson Cancer Center SPORE in Ovarian Cancer
|
5P50CA083639-14
|
$2,082,690
|
$124,961
|
BAST, ROBERT
|
UT MD ANDERSON CANCER CTR
|
|
The Role of SRC-1 in Breast Cancer
|
5R01CA112403-07
|
$253,549
|
$63,387
|
XU, JIANMING
|
BAYLOR COLLEGE OF MEDICINE
|
|
The NFkB-dependent Secretome and Invasion/Angiogenesis in Thyroid Cancer
|
5R01CA155512-03
|
$290,901
|
$145,451
|
HAUGEN, BRYAN
|
UNIVERSITY OF COLORADO DENVER
|
|
The MB-CCOP at Boston Medical Center
|
3U10CA139519-03S3
|
$501,282
|
$55,141
|
Kachnic, Lisa
|
BOSTON MEDICAL CENTER
|
|
The MB-CCOP at Boston Medical Center
|
3U10CA139519-03S4
|
$122,789
|
$13,507
|
Kachnic, Lisa
|
BOSTON MEDICAL CENTER
|
|
The Evaluation of Novel Therapeutics for Genitourinary Malignancies
|
ZIA SC 010098
|
$79,494
|
$3,975
|
Dahut, William
|
CCR (NCI)
|
|
The Brooklyn Minority-Based Community Clinical Oncology Program
|
3U10CA114671-07S1
|
$125,000
|
$18,750
|
Solomon, William
|
SUNY DOWNSTATE MEDICAL CENTER
|
|
The Brooklyn Minority-Based Community Clinical Oncology Program
|
5U10CA114671-07
|
$362,718
|
$54,408
|
Solomon, William
|
SUNY DOWNSTATE MEDICAL CENTER
|
|
The Bcl-2-p85/PI3K signaling axis
|
5R01CA140980-04
|
$368,938
|
$184,469
|
ZHANG, XIAO-KUN
|
SANFORD-BURNHAM MEDICAL RESEARCH INSTIT
|
|
Taxol: Mechanisms of Action and Resistance
|
5R01CA077263-13
|
$378,397
|
$378,397
|
HORWITZ, SUSAN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Targeting Stromal Collagen in Pancreatic Cancer
|
1R01CA169281-01A1
|
$408,227
|
$204,114
|
Han, Haiyong
|
TRANSLATIONAL GENOMICS RESEARCH INST
|
|
Targeting microtubule stabilization to reduce breast tumor metastasis
|
5R01CA154624-02
|
$299,402
|
$149,701
|
MARTIN, STUART
|
UNIVERSITY OF MARYLAND BALTIMORE
|
|
Targeting c-Myc and Akt with PP2A reactivation therapy for the treatment of breas
|
1R41CA165318-01A1
|
$300,000
|
$75,000
|
Christensen, Dale
|
ONCOTIDE PHARMACEUTICALS, INC.
|
|
Targeted Polymer Micelles for Treatment of Metastatic Melanoma
|
1R41CA177077-01
|
$139,587
|
$139,587
|
Sill, Kevin
|
INTEZYNE TECHNOLOGIES, LLC
|
|
TARGETED INTERVENTION OF BREAST ONCOGENIC PATHWAYS
|
5R01CA098473-09
|
$292,064
|
$73,016
|
SEBTI, SAID
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
Targeted Docetaxel-Nanocolloid for the Treatment of Ovarian Cancer
|
1U43CA162454-01A1
|
$288,302
|
$288,302
|
Coleman, Timothy
|
NEMUCORE MEDICAL INNOVATIONS, INC.
|
|
Taccalonolides: Mechanisms of Action and Cellular Resistance
|
5R01CA121138-08
|
$242,208
|
$60,552
|
Mooberry, Susan
|
UNIV OF TX HSC, SA
|
|
Synthesis, Biosynthesis, and Structure of Antitumor Agents
|
5R01CA076497-14
|
$262,270
|
$65,568
|
HOYE, THOMAS
|
UNIVERSITY OF MINNESOTA
|
|
Synergistic chemo-siRNA combination therapy
|
5R01CA158300-03
|
$350,134
|
$350,134
|
WIENTJES, M
|
OPTIMUM THERAPEUTICS, LLC
|
|
SWOG Community Clinical Oncology Program Research Base
|
7U10CA037429-29
|
$4,229,363
|
$380,643
|
BLANKE, CHARLES
|
OREGON HEALTH & SCIENCE UNIVERSITY
|
|
SunCoast CCOP Research Base at the University of South Florida
|
5U10CA081920-12
|
$2,305,668
|
$46,113
|
KRISCHER, JEFFREY
|
UNIVERSITY OF SOUTH FLORIDA
|
|
Stromal depletion for pancreatic cancer therapy
|
1R21CA176339-01
|
$129,195
|
$129,195
|
Li, Shyh-Dar
|
ONTARIO INSTITUTE FOR CANCER RESEARCH
|
|
Stroger Hospital of Cook County, MBCCOP
|
5U10CA095867-11
|
$743,820
|
$81,820
|
Lad, Thomas
|
HEKTOEN INSTITUTE FOR MEDICAL RESEARCH
|
Total relevant funding to Taxol for this search: $53,683,024
|